Inhibikase Therapeutics, Inc. (IKT) stock
IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.38−0.07 (-4.83%)
Close on Nov 17, 2026Market cap $192.56MP/E –Yield –
Inhibikase Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Inhibikase Therapeutics's enterprise value was $56.19M on Nov 11, 2026, against $36.39M a year earlier. Over the last 5 years it ranged from -$17.88M to $145.98M, with a median of $260.41K.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $56.19M | -26.1% |
| 2025 | Dec 31, 2025 | $76.03M | +259.3% |
| 2024 | Dec 31, 2024 | $21.16M | – |
| 2023 | Dec 29, 2023 | -$9.87M | – |
| 2022 | Dec 30, 2022 | -$13.78M | – |
| 2021 | Dec 31, 2021 | -$9.64M | – |
See a number that looks wrong?